Solid Biosciences Inc.
SLDBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Solid Biosciences Inc. focuses on Biotechnology services and products. Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. Valued at $1.10B, SLDB is a small-cap name in its sector. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Market Cap
$1.10B
Beta
2.44
P/E (TTM)
—
P/E (Fwd)
-5.87
EPS (TTM)
$-1.89
EPS (Fwd)
$-1.75
ROE
-65.5%
ROA
-36.4%
Cash
$377.7M
Total Debt
$20.2M
Free CF
-$118.2M
52W Change
99.8%
Annual Financials
Cash vs Debt
Where SLDB stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, SLDB finished 31.05% above its 150-day moving average ($7.73) and 41.88% above its 200-day moving average ($7.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLDB overbought or oversold?
At the August 28, 2026 close, SLDB's RSI(14) was 72.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Solid Biosciences Inc. holds $377.7M in cash against $20.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$118.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -65.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $8.1M (2022) to $0 (2025), a 100% decline worth watching.
Solid Biosciences Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SLDB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.